targeting 60c per share with growth, 8 baggers, page-34

"This approach was recently shown by the S$6m investment in PrIME Biologics which valued that business at S$60m (A$46m),. NuSep will continue to pursue this form of
funding so long as it allows the Company to unlock the value of assets relative to its share price. To this end the Company is evaluating similar investment possibilities for the SpermSep application of the PrIME technology"

*allows the Company to unlock the value of assets relative to its share price*--30c per share at least.

*without requiring NuSep shareholders to directly fund this
project.*

*NuSep has established an external valuation which is significantly above the total value of NuSep*